Table 1—

Baseline demographic characteristics and efficacy variables of patients valid for safety analysis

CharacteristicsAcarbosePlaceboP
n4043
Age (years)58.37 ± 10.762.39 ± 8.020.127*
Sex (%)0.259
 Female35.023.3
 Male65.076.7
Ethnicity (%)
 White80.097.7
 Asian5.00.0
 Others15.02.3
Weight (kg)89.77 ± 12.7387.88 ± 11.70.632*
BMI (kg/m2)30.75 ± 2.9630.09 ± 2.850.086*
Duration of diabetes (years)5.32 ± 4.556.06 ± 5.320.757
Daily metformin dosage (mg)1,700 (500–4,000)1,700 (500–3,000)0.490
HbAlc (%)8.05 ± 0.897.82 ± 0.830.498*
FBG (mmol/l)9.97 ± 2.479.41 ± 1.990.719*
  • Data are n, means ± SD, or median (min-max).

  • *

    * ANOVA with center and center by treatment interaction;

  • Cochran-Mantel-Haenszel test adjusting for center effect;

  • Wilcoxon’s rank-sum test.